The ECS has gained attention in AD research based on reports over the last two decades demonstrating the potential of cannabinoids to target Aβ and Tau metabolism, inflammation, mitochondrial dysfunction and excitotoxicity [105]. The gene discussed is MAPT; the disease is Alzheimer disease.